ASCO 2025: Modern Approaches to Metastatic Melanoma: Navigating the Treatment Landscape

Panelists discuss the significant advancements in metastatic melanoma treatment over the past decade, including targeted therapies and immunotherapy, to help clinicians navigate the evolving therapeutic landscape and improve patient outcomes.

EP. 1: Frontline Immunotherapy Treatment Options in Advanced or Metastatic Cutaneous Melanoma

June 25th 2025

Panelists discuss modern approaches to metastatic melanoma, focusing on recent advances in immunotherapy and cell therapies, individualized frontline treatment strategies, and evolving clinical data to guide clinicians in optimizing patient outcomes.

EP. 2: Choosing a Preferred Combination Immune Checkpoint Inhibitor (ICI) Regimen and Identifying Patients Appropriate for ICI Monotherapy

June 25th 2025

Panelists discuss frontline treatment preferences for metastatic melanoma, emphasizing the durability of combination immunotherapies like nivolumab plus ipilimumab, the emerging role of nivolumab plus relatlimab, and the importance of tailoring therapy based on disease characteristics, toxicity profiles, and individual patient factors.

EP. 3: Sequencing Therapy in BRAF V600-Mutant Metastatic Melanoma: The DREAMseq Trial

July 2nd 2025

Panelists discuss treatment sequencing for BRAF-mutated metastatic melanoma, highlighting evidence from the DREAMseq trial that supports starting with immunotherapy for better long-term survival while acknowledging clinical scenarios where rapid-response targeted therapy may be appropriate and emphasizing the need for flexibility based on patient condition and emerging data.

EP. 4: IL-6 Blockade and the Mitigation of ICI Toxicity

July 2nd 2025

Panelists discuss emerging strategies to reduce toxicity in dual immune checkpoint blockade for metastatic melanoma, focusing on promising early data with anti–IL-6 agents such as sarilumab. They acknowledge challenges around scalability, cost, and validation in broader populations and emphasize the importance of ongoing research and clinical trials to optimize tolerability without compromising efficacy.

EP. 5: The Role of ctDNA in the Diagnosis and Management of Metastatic Melanoma

July 9th 2025

Panelists discuss the evolving role of circulating tumor DNA (ctDNA) in metastatic melanoma management, recognizing its potential as a minimal residual disease (MRD) marker and monitoring tool while emphasizing current limitations, investigational status, and the need for further research to define its clinical utility.

EP. 6: Treatment Options for Relapsed Metastatic Cutaneous Melanoma

July 9th 2025

Panelists discuss expanding treatment options beyond frontline therapy for metastatic melanoma, emphasizing the use of targeted therapies, combination immunotherapies, and emerging modalities such as oncolytic virus and adoptive cell therapy while highlighting the balance between efficacy, toxicity, patient-centered outcomes, and practical challenges in clinical decision-making.

EP. 7: The Challenge Treating Brain Metastases and Leptomeningeal Disease (LMD)

July 16th 2025

Panelists discuss the challenges of managing brain metastases in patients with melanoma after frontline therapy, highlighting the roles of localized treatments, targeted therapies for actionable mutations, limited options for symptomatic cases, and the urgent need for improved strategies for central nervous system (CNS) and leptomeningeal disease (LMD) management.

EP. 8: Lifileucel: Filling an Unmet Need and Providing Long-Term Benefit

July 16th 2025

Panelists discuss 5-year data from a trial of lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy, highlighting its promising long-term survival benefits and growing role in standard care for advanced cancers, especially in patients unresponsive to prior treatments.

EP. 9: The Importance of Identifying Patients Appropriate for Lifileucel Treatment Early in the Disease Course

July 23rd 2025

Panelists discuss the critical importance of early referral and coordinated communication between community oncologists and treatment centers to ensure timely evaluation and access to tumor-infiltrating lymphocyte (TIL) therapy, emphasizing outreach efforts to raise awareness and streamline patient pathways.

EP. 10: Lifileucel: Leveraging Multidisciplinary Care Coordination and Community Outreach

July 23rd 2025

Panelists discuss the need for early, coordinated, and multidisciplinary care to ensure timely access to tumor-infiltrating lymphocyte (TIL) therapy, highlighting the importance of integrated communication, patient-centered planning, and shared decision-making—especially for older patients navigating complex treatment choices.

EP. 11: An Introduction to T-cell Receptor T-cell (TCR-T) Therapy

July 30th 2025

Panelists discuss the distinctions among tumor-infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR) T-cell, and T-cell receptor T-cell (TCR-T) therapies in melanoma, emphasizing TIL therapy’s polyclonal nature and regulatory challenges while highlighting the promise of engineered TCR-T cells and the need to balance scientific validation with clinical feasibility to maintain access to innovative treatments.

EP. 12: Understanding PRAME Expression and the SUPRAME Phase 3 Clinical Trial Design

July 30th 2025

Panelists discuss the emerging role of PRAME-targeted T-cell receptor T-cell (TCR-T) therapies in melanoma, highlighting a novel clinical trial comparing TCR-T and tumor-infiltrating lymphocyte (TIL) treatments that focuses on HLA-A*02:01-positive patients and aims to provide patient-friendly, outpatient-compatible options with faster manufacturing timelines.

EP. 13: RP1: An Emerging Intratumoral Therapy

August 6th 2025

Panelists discuss the promising systemic responses of RP1, an oncolytic virus therapy for melanoma, emphasizing its expanded applicability through visceral tumor injection and the need for further data to optimize dosing strategies and confirm durability compared with other treatments.

EP. 14: Looking Ahead to the Changing Treatment Landscape for Metastatic Cutaneous Melanoma

August 6th 2025

Panelists discuss the complexities of selecting among second- and third-line therapies such as tumor-infiltrating lymphocyte (TIL), T-cell receptor T-cell (TCR-T), and oncolytic viruses, emphasizing that treatment choice will depend on emerging data, patient factors, practical considerations, and quality of life, with ongoing trials and clinical experience guiding optimal sequencing.

x